Reporting Checklist for Nature Neuroscience

Similar documents
Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience

Life Sciences Reporting Summary

Life Sciences Reporting Summary

Our web collection on statistics for biologists may be useful.

Jeffrey W. Elias, PhD UCD SOM Office of Research Grants Facilitation.

Efforts to Improve Data Transparency at the JBC

Revision Checklist for Science Signaling Research Manuscripts: Data Requirements and Style Guidelines

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)

Archives of Scientific Psychology Reporting Questionnaire for Manuscripts Describing Primary Data Collections

SUPPLEMENTARY INFORMATION

BIOEQUIVALENCE TRIAL INFORMATION

BIOSTATISTICS AND MEDICAL INFORMATICS (B M I)

PROMOTING TRANSPARENT RESEARCH METHODS, PROTOCOLS AND DATA TO REDUCE IRREPRODUCIBILITY

Animal Research Ethics Committee. Guidelines for Submitting Protocols for ethical approval of research or teaching involving live animals

Medicines Control Authority Of Zimbabwe

David M. Rocke Division of Biostatistics and Department of Biomedical Engineering University of California, Davis

Cerebrospinal fluid tau, neurogranin and neurofilament light in Alzheimerís disease

Real-time RT PCR. for identification of differentially expressed genes. (with Schizophrenia application) Rolf Sundberg, Stockholm Univ.

ENCODE RBP Antibody Characterization Guidelines

Jiali Li, Sukhvir P Mahal, Cheryl A Demczyk and Charles Weissmann

Precision in Quantitative Imaging: Trial Development and Quality Assurance

Exploration and Analysis of DNA Microarray Data

Edinburgh Research Explorer

Design of Experiments (DOE) Instructor: Thomas Oesterle

Gene expression: Microarray data analysis. Copyright notice. Outline: microarray data analysis. Schedule

Discussion Solution Mollusks and Litter Decomposition

Technical Review. Real time PCR

ALLEN Human Brain Atlas

BIOSTATISTICAL METHODS

Methods in Clinical Cancer Research Workshop Format for Protocol Concept Synopsis Sheet (blank) SYNOPSIS

Hierarchical Linear Modeling: A Primer 1 (Measures Within People) R. C. Gardner Department of Psychology

SUPPLEMENTARY INFORMATION

3.1.4 DNA Microarray Technology

The Kruskal-Wallis Test with Excel In 3 Simple Steps. Kilem L. Gwet, Ph.D.

Reporting Summary. Statistical parameters. Software and code. nature research reporting summary April Corresponding author(s):

THE LEAD PROFILE AND OTHER NON-PARAMETRIC TOOLS TO EVALUATE SURVEY SERIES AS LEADING INDICATORS

SUPPLEMENTARY FIGURES

Proteomics 6/4/2009 WESTERN BLOT ANALYSIS

CHAPTER 5 RESULTS AND ANALYSIS

CHAPTER 8 T Tests. A number of t tests are available, including: The One-Sample T Test The Paired-Samples Test The Independent-Samples T Test

Using Excel s Analysis ToolPak Add-In

Estoril Education Day

Bios 6648: Design & conduct of clinical research

Biostatistics for Public Health Practice

Lab 1: A review of linear models

Our web collection on statistics for biologists may be useful.

CHAPTER 17 Brain Image Analysis and Atlas Construction

Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi

Q: Using at least 3 biological replicates in an experiment is recommended to do. What do you suggest: At which step of calculation of the relative

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

Alternative TSSs are co-regulated in single cells in the mouse brain

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.

Microarray Gene Expression Analysis at CNIO

Common Issues in Qualification and Validation of Analytical Procedures

Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products

Distinguish between different types of numerical data and different data collection processes.

QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES FOCUS ON MICROSAMPLING

Field trial with veterinary vaccine

A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms

QTL mapping in mice. Karl W Broman. Department of Biostatistics Johns Hopkins University Baltimore, Maryland, USA.

36.2. Exploring Data. Introduction. Prerequisites. Learning Outcomes

Heterogeneity Random and fixed effects

QPCR ASSAYS FOR MIRNA EXPRESSION PROFILING

Detection of Action Potentials In Vitro by Changes in Refractive Index

Nature Neuroscience: doi: /nn Supplementary Figure 1

Views of a Clinical Study Report

iphemap: An atlas of Phenotype to genotype relationships of human ipsc models of neurological diseases

HOON SOHN CHARLES R. FARRAR

BINF 6010 ITSC 8010 Spring 2010 Biotechnology & Genomics Lab Experimental Design- Technical.

Model construction of earning money by taking photos

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

Validation Using SDS Software Version on the Applied Biosystems 7500 Real-Time PCR System and the ABI PRISM 7000 Sequence Detection System

EECS730: Introduction to Bioinformatics

Designing Functional Genomics Experiments for Successful Analysis RORY STARK 18 SEPTEMBER 2017

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

Evaluation with RNA ScreenTape Assays

JGK TRAINING PROGRAMME MODULE 2: METHOD VALIDATION AND MEASUREMENT OF UNCERTAINTY IN VETERINARY LABORATORIES PRACTICAL COURSE

Gene Expression Profiling of Prokaryotic Samples using Low Input Quick Amp WT Kit

Important Information for MCP Authors

Untangling Correlated Predictors with Principle Components

Practical What & Where of Rigor and Reproducibility in the NIH Application. SIU School of Medicine Office of Grants & Contracts with Sophia Ran, PhD

Transcription:

Corresponding Author: Manuscript Number: Manuscript Type: Rachel Wilson NNA48246B Article Reporting Checklist for Nature Neuroscience # Main Figures: 8 # Supplementary Figures: 7 # Supplementary Tables: 0 # Supplementary Videos: 0 This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. For more information, please read Reporting Life Sciences Research. Please note that in the event of publication, it is mandatory that authors include all relevant methodological and statistical information in the manuscript. Statistics reporting, by figure Please specify the following information for each panel reporting quantitative data, and where each item is reported (section, e.g. Results, & paragraph number). Each figure should ideally contain an exact sample size (n) for each experimental group/condition, where n is an exact number and not a range, a clear definition of how n is defined (for example x cells from x slices from x animals from x litters, collected over x days), a description of the statistical test used, the results of the tests, any descriptive statistics and clearly defined error bars if applicable. For any experiments using custom statistics, please indicate the test used and stats obtained for each experiment. Each figure should include a statement of how many times the experiment shown was replicated in the lab; the details of sample collection should be sufficiently clear so that the replicability of the experiment is obvious to the reader. For experiments reported in the text but not in the figures, please use the paragraph number instead of the figure number. Note: Mean and standard deviation are not appropriate on small samples, and plotting independent data is usually more informative. When technical replicates are reported, error and significance measures reflect the experimental variability and not the variability of the biological process; it is misleading not to state this clearly. TEST USED n DESCRIPTIVE STATS (AVERAGE, VARIANCE) P VALUE DEGREES OF FREEDOM & F/t/z/R/ETC VALUE FIGURE NUMBER WHICH TEST? EXACT VALUE DEFINED? REPORTED? EXACT VALUE VALUE example 1a oneway ANOVA Fig. 9, 9, 10, 15 mice from at least 3 litters/group Methods para 8 error bars are mean / SEM Fig. p = 0.044 Fig. F(3, 36) = 2.97 Fig. example results, unpaired t test Results 15 slices from 10 mice Results error bars are mean / SEM Results p = 0.0006 Results t(28) = 2.808 Results 1c 19 cells from 19 animals error bars are mean / sem 1

FIGURE NUMBER 1eg TEST USED WHICH TEST? EXACT VALUE 17 (PNs), 4 ORNs n DEFINED? PNs in 17 animals, ORNs in 4 animals DESCRIPTIVE STATS (AVERAGE, VARIANCE) REPORTED? mean in black, sd shown as a gray band 2c 13 cells in 13 animals means 2d 7/6 cells in 7/6 animals (for 2 different drug conditions) means P VALUE EXACT VALUE DEGREES OF FREEDOM & F/t/z/R/ETC VALUE VALUE 2f 7/6 cells in 7/6 animals error bars are mean / sem 3b 17 cells in 17 animals means 3c paired ttest 17 cells in 17 animals 7.0e6 3d paired ttest 17 cells in 17 animals 3.8e4 3e paired ttest 8 cells in 8 animals 2.5e3 4ac 17 cells in 17 animals means (/ sem in panels bc) 4d 17 cells in 17 animals means 4e paired ttest 17 cells in 17 animals 5.2e5 4f 17 cells in 17 animals means 4g paired ttest 17 cells in 17 animals 1.4e3 5bc 45 cells in 38 animals means 5d 22 cells in 22 animals mean 5e 9 cells in 8 animals mean 5f unpaired t test 22/9 22 cells in 22 animals/9 cells in 8 animals 1.7e3 5g 5 cells in 5 animals means 6c 4 cells in 4 animals mean 6e 7 cells in 7 animals mean 6f 7 cells in 7 animals mean legen d, metho ds 2

Representative figures 1. Are any representative images shown (including Western blots and immunohistochemistry/staining) in the paper? If so, what figure(s)? 2. For each representative image, is there a clear statement of how many times this experiment was successfully repeated and a discussion of any limitations in repeatability? If so, where is this reported (section, paragraph #)? Representative traces are shown in figures 1b, 1e, 2a, 2b, 3a, 5a, 6c and 6d. For traces in figure 1b, 1e, 3a, 5a, 6c and 6d, representative traces are immediately followed by mean data with number of repeats given in the. Variances are indicated by error bars or by showing (see above chart). Traces in figure 2a are from 2 cells with unusually low spontaneous EPSC rates which allows us to clearly see two components of the EPSC decay. This is noted in the figure. In cells with higher EPSC rates, overlap between nearby EPSCs makes their kinetics hard to discern. Averaging together EPSCs (instead of showing single examples) could create a spurious impression of slow kinetics. Therefore, we elected to show example data only to make this point. Statistics and general methods 1. Is there a justification of the sample size? If so, how was it justified? Even if no sample size calculation was performed, authors should report why the sample size is adequate to measure their effect size. Prior studies have established that the PNs we are studying are identifiable across animals and have quite consistent physiological properties. Therefore, our expectation was that even small effects should be visible with relatively small sample sizes, and this turned out to be true. We decided on a sample size based on the degree of consistency in our pilot data (which was high), together with the difficulty of performing these experiments (which was also high). 2. Are statistical tests justified as appropriate for every figure? Paired ttests (2tailed) were used to compare responses before and after drug application in figures 3ce, 4e, and 4g. p values are given in figure s. A nonpaired 2tailed ttest was used to compare responses of two different labeled cell types in figure 5f. The p value is also given in the,. a. If there is a section summarizing the statistical methods in the methods, is the statistical test for each experiment clearly defined? The type of test is noted in the. 3

b. Do the data meet the assumptions of the specific statistical test you chose (e.g. normality for a parametric test)? Where is this described (section, paragraph #)? For all statistical tests, are shown in the figure. We used parametric tests throughout the study. According to a standard text in the field ( Primer of Biostatistics, by Dr. Stanton Glantz, McGrawHill 2011), [H]ow can you tell whether the assumptions such as normality are met? The simplest approach is to plot the observations and look at them. Do they seem compatible with the assumptions that they were drawn from normally distributed populations with roughly the same variances, that is, within a factor of 2 to 3 of each other? If so, you are probably safe in using parametric methods [e.g., ttests].. One can also construct a chi^2 statistic. [but] in practice simply looking at the data is generally adequate.[y]our choice of approach (i.e., parametric versus nonparametric) often has to be based more on judgment and preference than hard evidence. Things basically come down to the following difference of opinion: Some people think that in the absence of evidence that the data were not drawn from a normally distributed population, one should use parametric tests because they are more powerful and more widely used. These people say that you should use a nonparametric test only when there is positive evidence that the populations under study are not normally distributed. Others point out that the nonparametric methods are 95 percent as powerful as parametric methods when the data are from normally distributed populations and more reliable when the data are not from normally distributed populations. At the moment there is no definitive answer stating which attitude is preferable. And there probably never will be such an answer. We have followed the visual inspection procedure, and it indicates that an assumption of normality is compatible with our data. We take the position that a parametric test should be the default, which is a widelyheld position among statisticians, as indicated by this passage. c. Is there any estimate of variance within each group of data? Is the variance similar between groups that are being statistically compared? Where is this described (section, paragraph #)? Variance within each group is shown through plots of individual data. d. Are tests specified as one or twosided? All tests are 2sided. e. Are there adjustments for multiple comparisons? No adjustments were performed, because we never considered a set of hypotheses simultaneously. 3. Are criteria for excluding data reported? Was this criterion established prior to data collection? Where is this described (section, paragraph #)? 4. Define the method of randomization used to assign subjects (or samples) to the experimental groups and to collect and process data. Current clamp recordings were terminated if odors failed to elicit spiking responses in labeled cells (Methods, "Electrophysiology"). Voltage clamp responses to nerve stimulation were terminated if we were unable to elicit a stable EPSC waveform (Methods, "Electrical stimulation of ORN axons") Voltage clamp responses to no randomization was used If no randomization was used, state so. Where does this appear (section, paragraph #)? 4

5. Is a statement of the extent to which investigator knew the group allocation during the experiment and in assessing outcome included? If no blinding was done, state so. 6. For experiments in live vertebrates, is a statement of compliance with ethical guidelines/regulations included? 7. Is the species of the animals used reported? no blinding was done all experiments were performed in invertebrates Yes: abstract, Introduction (paragraph 4). 8. Is the strain of the animals (including background strains of KO/ transgenic animals used) reported? Yes: methods, "Fly stocks" 9. Is the sex of the animals/subjects used reported? Yes: methods, "Fly stocks" 10. Is the age of the animals/subjects reported? Yes: methods, "Fly stocks" 11. For animals housed in a vivarium, is the light/dark cycle reported? Yes: methods, "Fly stocks" 12. For animals housed in a vivarium, is the housing group (i.e. number of animals per cage) reported? Flies were raised in standard culture bottles at typical densities. 13. For behavioral experiments, is the time of day reported (e.g. light or dark cycle)? 14. Is the previous history of the animals/subjects (e.g. prior drug administration, surgery, behavioral testing) reported? a. If multiple behavioral tests were conducted in the same group of animals, is this reported? 15. If any animals/subjects were excluded from analysis, is this reported? 5

Reagents a. How were the criteria for exclusion defined? Where is this described (section, paragraph #)? b. Specify reasons for any discrepancy between the number of animals at the beginning and end of the study. Where is this described (section, paragraph #)? 1. Have antibodies been validated for use in the system under study (assay and species)? All antibodies used in this study have been previously published (Wilson and Laurent 2005). a. Is antibody catalog number given? Where does this appear (section, paragraph #)? not in this manuscript. b. Where were the validation data reported (citation, supplementary information, Antibodypedia)? Where does this appear (section, paragraph #)? This reference is in main text (Wilson and Laurent 2005), Methods. 2. If cell lines were used to reflect the properties of a particular tissue or disease state, is their source identified? a. Were they recently authenticated? Where is this information reported (section, paragraph #)? Data deposition Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Microarray data Deposition is strongly recommended for many other datasets for which structured public repositories exist; more details on our data policy are available here. We encourage the provision of other source data in supplementary information or in unstructured repositories such as Figshare and Dryad. 1. Are accession codes for deposit dates provided? 6

Computer code/software Any custom algorithm/software that is central to the methods must be supplied by the authors in a usable and readable form for readers at the time of publication. However, referees may ask for this information at any time during the review process. 1. Identify all custom software or scripts that were required to conduct the study and where in the procedures each was used. Custom Matlab scripts were used to analyze data and to model synaptic transmission and inhibition (Figures 1, 2, 4, 7, 8). Analysis and modeling are described in Methods. Additional details and validation of the models is presented in supplementary figures. The Methods describe which models were used to generate which figures. 2. Is computer source code/software provided with the paper or deposited in a public repository? Indicate in what form this is provided or how it can be obtained. Code will be publicly available following review and publication. We are depositing the code in the ModelDB archive, a public repository for computational neuroscience models (http:// senselab.med.yale.edu/modeldb/). Human subjects 1. Which IRB approved the protocol? Where is this stated (section, paragraph #)? 2. Is demographic information on all subjects provided? 3. Is the number of human subjects, their age and sex clearly defined? 4. Are the inclusion and exclusion criteria (if any) clearly specified? 5. How well were the groups matched? Where is this information described (section, paragraph #)? 6. Is a statement included confirming that informed consent was obtained from all subjects? 7. For publication of patient photos, is a statement included confirming that consent to publish was obtained? 7

fmri studies For papers reporting functional imaging (fmri) results please ensure that these minimal reporting guidelines are met and that all this information is clearly provided in the methods: 1. Were any subjects scanned but then rejected for the analysis after the data was collected? a. If yes, is the number rejected and reasons for rejection described? 2. Is the number of blocks, trials or experimental units per session and/ or subjects specified? 3. Is the length of each trial and interval between trials specified? 4. Is a blocked, eventrelated, or mixed design being used? If applicable, please specify the block length or how the eventrelated or mixed design was optimized. 5. Is the task design clearly described? 6. How was behavioral performance measured? 7. Is an ANOVA or factorial design being used? 8. For data acquisition, is a whole brain scan used? If not, state area of acquisition. a. How was this region determined? 9. Is the field strength (in Tesla) of the MRI system stated? a. Is the pulse sequence type (gradient/spin echo, EPI/spiral) stated? b. Are the fieldofview, matrix size, slice thickness, and TE/TR/ flip angle clearly stated? 10. Are the software and specific parameters (model/functions, smoothing kernel size if applicable, etc.) used for data processing and preprocessing clearly stated? 8

11. Is the coordinate space for the anatomical/functional imaging data clearly defined as subject/native space or standardized stereotaxic space, e.g., original Talairach, MNI305, ICBM152, etc? Where (section, paragraph #)? 12. If there was data normalization/standardization to a specific space template, are the type of transformation (linear vs. nonlinear) used and image types being transformed clearly described? Where (section, paragraph #)? 13. How were anatomical locations determined, e.g., via an automated labeling algorithm (AAL), standardized coordinate database (Talairach daemon), probabilistic atlases, etc.? 14. Were any additional regressors (behavioral covariates, motion etc) used? 15. Is the contrast construction clearly defined? 16. Is a mixed/random effects or fixed inference used? a. If fixed effects inference used, is this justified? 17. Were repeated measures used (multiple measurements per subject)? a. If so, are the method to account for within subject correlation and the assumptions made about variance clearly stated? 18. If the threshold used for inference and visualization in figures varies, is this clearly stated? 19. Are statistical inferences corrected for multiple comparisons? a. If not, is this labeled as uncorrected? 20. Are the results based on an ROI (region of interest) analysis? a. If so, is the rationale clearly described? b. How were the ROI s defined (functional vs anatomical localization)? 21. Is there correction for multiple comparisons within each voxel? 22. For clusterwise significance, is the clusterdefining threshold and the corrected significance level defined? 9

Additional comments Additional Comments 10